natgillin/translations-raw huggingface dataset:
These were considered to result from a deficiency of vitamin K following a reduction in the absorption of fat-soluble vitamins (see section 4.4).
Obravnavalo se je, kot da so se pojavile kot posledica pomanjkanja vitamina K zaradi zmanjšane absorpcije v maščobi topnih vitaminov (glejte poglavje 4.4).
This is because your doctor may want to monitor your health, change the dose of BindRen or the other medicine you are taking or tell you to not take BindRen and the other medicine at the same time.
To je zato, ker morda želi vaš zdravnik spremljati vaše zdravje, spremeniti odmerek zdravila BindRen ali drugega zdravila, ki ga jemljete, ali pa vam želi povedati, da ne jemljite zdravila BindRen hkrati z drugimi zdravili.
Two long-term, open-label, flexible-dose studies demonstrated that serum phosphorus reduction was maintained for up to one year.
Dve dolgoročni, odprti študiji s prilagodljivimi odmerki sta dokazali, da se je znižanje fosforja v serumu ohranilo do enega leta.
What BindRen is and what it is used for
Kaj je zdravilo BindRen in za kaj ga uporabljamo
Changes in systemic ion balance with an increase in chloride and decrease in bicarbonate are therefore possible.
Zato so možne spremembe v sistemskem ravnovesju ionov z zvišanjem klorida in znižanjem bikarbonata.
BindRen should not be used in children and adolescents.
Zdravila BindRen se pri otrocih in mladostnikih ne sme uporabljati.
What BindRen is and what it is used for What you need to know before you take BindRen How to take BindRen
Kaj je zdravilo BindRen in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo BindRen
Intestinal obstruction and ileus/subileus
Zapora črevesja in ileus/subileus
In these patients, monitoring of vitamin A, D and E concentrations or assessing vitamin K status through the measurement of coagulation parameters is recommended and the vitamins should be supplemented if necessary.
Pri teh bolnikih se priporoča spremljati koncentracije vitaminov A, D in E ali oceniti status vitamina K z merjenjem koagulacijskih parametrov, po potrebi pa je treba dodajati vitamine.
Manufacturer allphamed PHARBIL Arzneimittel GmbH Hildebrandstr.
Izdelovalec allphamed PHARBIL Arzneimittel GmbH Hildebrandstr.
Patients with severe hepatic impairment were excluded from clinical studies.
Bolniki s hudo okvaro jeter so bili izključeni iz kliničnih študij.
The reductions in LDL-cholesterol are also reflected in significant falls in total cholesterol.
Znižanje LDL-holesterola se kaže tudi v močnem znižanju celokupnega holesterola.
BindRen does not contain calcium and your doctor may prescribe additional calcium tablets.
Zdravilo BindRen ne vsebuje kalcija, zato vam lahko zdravnik predpiše dodatne tablete kalcija.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Therefore, the use of BindRen is not recommended in patients with severe hepatic impairment (see also section 4.4).
Zato se uporaba zdravila BindRen ne priporoča pri bolnikih s hudo okvaro jeter (glejte tudi poglavje 4.4).
Patients should be encouraged to adhere to their prescribed low phosphate diets.
Bolnike je treba spodbuditi, da se držijo svojih diet z nizko vsebnostjo fosfata.
When administering any medicinal product where a reduction in the bioavailability could have a clinically relevant effect on safety or efficacy, the medicinal product should be administered at least 1 hour before, or 3 hours after taking BindRen.
Pri dajanju zdravil, kjer ima lahko znižanje biološke razpoložljivosti klinično pomemben učinek na varnost ali učinkovitost, je treba zdravilo dati vsaj 1 uro pred uporabo zdravila BindRen ali 3 ure po tem.
Coronary artery disease
bolezen koronarne arterije
In most clinical studies, colestilan decreased serum PTH compared to baseline, and was statistically significant against placebo.
V večini kliničnih študij je kolestilan znižal PTH v serumu v primerjavi z izhodiščem, znižanje pa je bilo v primerjavi s placebom statistično značilno.
It is recommended that you take the tablets whole with meals and with a small amount of water.
Priporočljivo je, da celo tableto pogoltnete z obrokom ali z majhno količino vode.
Two similar 12-week, open-label, flexible-dose studies followed by a 4-week double-blind withdrawal period (comparison to placebo) were performed.
Opravili so dve podobni 12-tedenski odprti študiji s prilagodljivim odmerkom, ki jima je sledilo 4-tedensko dvojno slepo odtegnitveno obdobje (v primerjavi s placebom).
If an acceptable serum phosphorus concentration is not achieved, the dose may be increased by 3 g per day (1 g three times daily) in 2-3 weekly intervals.
Če sprejemljiva koncentracija fosforja v serumu ni dosežena, se lahko odmerek zviša za 3 g na dan (1 g trikrat na dan) v 2-3-tedenskih intervalih.
If you forget to take BindRen
Če ste pozabili vzeti zdravilo BindRen
Serum glycosylated haemoglobin A1c
Glikozirani hemoglobin v serumu A1c
For more information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
Colestilan is a non-absorbed, non-calcium, non-metallic phosphate-binding polymer.
Kolestilan je neabsorpcijski, nekalcijevi, nekovinski polimer, ki veže fosfat.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release allphamed PHARBIL Arzneimittel GmbH Hildebrandstr.
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca, odgovornega za sproščanje serij allphamed PHARBIL Arzneimittel GmbH Hildebrandstr.
Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.
Znotraj vsake skupine pogostosti so neželeni učinki na zdravilo navedeni po padajoči resnosti.
The safety and efficacy of BindRen in children and adolescents aged under 18 years has not yet been established.
Varnost in učinkovitost zdravila BindRen pri otrocih in mladostnikih, starih manj kot 18 let, še nista bili dokazani.
Your doctor may advise you to take calcium, vitamin D supplements and other vitamins or other medicines in addition to BindRen.
Vaš zdravnik vam bo morda svetoval, da jemljete dodatke kalcija, vitamina D in drugih vitaminov ali zdravil poleg zdravila BindRen.
Fax: +49 211 - 520 544 99
Nemčija tel: +49 211 - 520 544 33 faks: +49 211 - 520 544 99
It is used to lower high blood phosphorus levels in adult patients undergoing dialysis due to poor kidney function.
Uporablja se za nižanje visokih ravni fosforja v krvi pri odraslih bolnikih na dializi zaradi slabega delovanja ledvic.
Constipation is common and if you suffer from persistent or worsening constipation please tell your doctor or pharmacist as this may be the first sign of blockage of your intestines.
Zaprtje je pogosto in če se poslabša, obvestite svojega zdravnika ali farmacevta, saj je to lahko prvi znak zapore črevesja.
They are supplied in blisters or bottles in cartons of 45, 99, 198, 270 or 297 tablets.
Na voljo so v pretisnih omotih ali plastenkah v škatlah po 45, 99, 198, 270 ali 297 tablet.
Vitamin K deficiency, calciphylaxis, electrolyte imbalance, fluid overload
pomanjkanje vitamina K, kalcifilaksa, neravnovesje elektrolitov, preobremenitev organizma s tekočino
Colestilan also showed significant reductions from baseline by 35.3 and 30.1% at week 12 in two flexible-dose studies, and by 25.8% after one year in long-term studies.
Kolestilan je pokazal tudi znatno znižanje od izhodišča za 35,3 in 30,1 % v 12. tednu v dveh študijah s prilagodljivimi odmerki, in za 25,8 % po enem letu v dolgoročnih študijah.
White, cylindrical, film-coated granules, each approximately 3.5 mm in length and 3 mm in diameter.
Bela, cilindrična, filmsko obložena zrnca, dolga približno 3,5 mm in s premerom približno 3 mm.
The maximum daily dose of BindRen tested in clinical trials was 15 g per day (5 g three times daily).
Največji dnevni odmerek zdravila BindRen, testiran v kliničnih preskušanjih, je bil 15 g na dan (5 g trikrat na dan).
Take BindRen by mouth.
Zdravilo BindRen zaužijte skozi usta.
- you have abnormally high levels of calcium in your blood due to overactivity of the parathyroid glands.
- imate nenormalno visoke ravni kalcija v krvi zaradi prevelike aktivnosti obščitničnih žlez.
BindRen binds phosphate and bile acid, with the release of chloride which is available for systemic absorption.
Zdravilo BindRen veže fosfat in želodčno kislino s sproščanjem klorida, ki je razpoložljiv za sistemsko absorpcijo.
Treatment of high blood phosphorus levels is usually required for a long period of time.
Zdravljenje visokih ravni fosforja v krvi je običajno dolgotrajno.
Serum calcium concentrations should be monitored as a normal follow-up of a dialysis patient.
Koncentracije kalcija v serumu je treba nadzirati v okviru normalnih pregledov bolnikov na dializi.
Granules 30 sachets 60 sachets 90 sachets
30 vrečic 60 vrečic 90 vrečic
Patients with renal insufficiency may develop hypocalcaemia or hypercalcaemia.
Pri bolnikih z ledvično insuficienco se lahko razvije hipokalciemija ali hiperkalciemija.
This may show as either fresh or altered blood in your vomit, or when from the lower bowel, as a black stool or with blood mixed in your stool.
To se lahko pokaže kot sveža ali stara kri v vašem bruhanju ali, kadar je v spodnjem delu želodca, kot črno blato ali kri,
Tablets should be taken whole.
Tablete se jemljejo cele.
No direct effects of BindRen are thus anticipated.
Zato ni moč pričakovati neposrednih učinkov zdravila BindRen.
The safety and efficacy of BindRen has not been studied in patients with:
Varnosti in učinkovitosti zdravila BindRen niso preučili pri bolnikih s/z:
If you do become pregnant or you are breast-feeding, and your doctor decides that you should continue your treatment with BindRen, your doctor may ask you to also take vitamin supplements.
Če zanosite ali začnete dojiti, in se vaš zdravnik odloči, da morate zdravljenje z zdravilom BindRen nadaljevati, vam bo zdravnik morda naročil tudi, da jemljete vitaminske dodatke.
BindRen tablets are white oval shaped film-coated tablets printed with “BINDREN” in blue ink on one side.
Zdravilo BindRen tablete so bele filmsko obložene tablete ovalne oblike z modrim napisom »BINDREN« na eni strani.
No data are available to assess the safety and efficacy in pregnant women.
Nosečnost Podatkov za oceno varnosti in učinkovitosti pri nosečnicah ni.
Patients received doses of up to 15 g per day, in three divided doses of 5 g.
Bolniki so prejemali odmerke do 15 g na dan, razdeljene na 3 odmerke po 5 g.
A tabulated list of frequencies was defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Neželeni učinki v obliki preglednice so bili razvrščeni po naslednjem pogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
If you take more BindRen than you should If you take too much BindRen, tell your doctor or pharmacist.
Če ste vzeli večji odmerek zdravila BindRen, kot bi smeli Če ste vzeli preveč zdravila BindRen, obvestite svojega zdravnika ali farmacevta.
Haematoma, hypotension
hematom, hipotenzija
No data on the use of BindRen in pre-dialysis patients are available.
Podatki o uporabi zdravila BindRen pri bolnikih pred dializo niso na voljo.
Concomitant treatment with medicinal products with a narrow therapeutic window requires close monitoring of drug concentrations or adverse reactions, on initiation or dose-adjustment of either BindRen or the concomitant medicinal product.
Sočasno zdravljenje z zdravili z ozkim terapevtskim oknom zahteva skrbno nadziranje koncentracij zdravil ali neželenih učinkov ob uvedbi ali prilagoditvi odmerka za zdravilo BindRen ali za zdravilo, ki se uporablja sočasno.
If you have to take other medicines your doctor will tell you if you can take the other medicines at the same time as BindRen or if you need to take the other medicines 1 hour before or 3 hours after taking BindRen.
Če morate jemati tudi druga zdravila, vam bo zdravnik povedal, ali lahko druga zdravila jemljete sočasno z zdravilom BindRen ali morate druga zdravila jemati 1 uro pred ali 3 ure po jemanju zdravila BindRen.
Indigo carmine aluminium lake (E 132) Carnauba wax
Črnilo šelak indigo karmin, aluminijev lak (E 132) karnauba vosek
However, even though you are taking BindRen, you must also follow the special diet recommended by your doctor.
Vendar pa se morate kljub jemanju zdravila BindRen držati posebnih prehranskih priporočil svojega zdravnika.
Granules should be taken whole as one dose from the sachet.
Vsa zrnca je treba vzeti kot en odmerek iz vrečice.
In these patients, monitoring serum folate status and supplementation with folic acid should be considered.
Pri teh bolnikih je treba razmisliti o nadziranju statusa folata v serumu in dodajanje folne kisline.
By binding phosphate from food in the digestive tract, colestilan lowers the serum phosphorus concentration.
Z vezavo fosfatov iz hrane v prebavni trakt kolestilan zniža koncentracije fosforja v serumu.
The binding sites become partially protonated in the stomach and interact through ionic and hydrogen bonding with both dietary phosphate anions and bile acids in the duodenum.
Mesta vezave se v želodcu delno protonizirajo in interagirajo z vezavo ionov in vodikov na fosfatne anione v hrani in želodčne kisline v dvanajsterniku.
Pack sizes of 45, 99, 198, 270 or 297 tablets per carton.
Velikosti pakiranja 45, 99, 198, 270 ali 297 tablet na škatlo.
White, oval shaped, film-coated tablet approximately 20.2 mm in length and 10.7 mm wide printed with “BINDREN” (in blue ink) on one side.
Filmsko obložena tableta Bela, ovalna, filmsko obložena tableta, dolga približno 20,2 mm in široka približno 10,7 mm z napisom »BINDREN« (z modrim črnilom) na eni strani.
BindRen has been given to dialysis patients in doses up to 15 g/day for up to one year continuously with no cases of overdose.
Zdravilo BindRen so neprekinjeno dajali bolnikom na dializi v odmerkih do 15 g/dan do enega leta brez primerov prevelikega odmerjanja.
The most serious side effects are bleeding from the stomach or lower bowel (uncommon).
Najresnejši neželeni učinki so krvavitev v trebuh ali spodnji del črevesja (občasni).
BindRen granules are white cylindrical granules.
Zdravilo BindRen zrnca so bela cilindrična zrnca.
Colestilan reduced calcium-phosphorus ion product by 0.90 mmol2/L2 after one year.
Kolestilan je po enem letu znižal produkt ionov kalcija in fosforja za 0,90 mmol2/l2.
In a double-blind, 12-week fixed-dose study with five colestilan groups (3, 6, 9, 12 and 15 g/day) and placebo, colestilan at 6 g/day and above demonstrated a dose-dependent reduction in serum phosphorus level.
V dvojno slepi, 12 tednov trajajoči študiji s fiksnim odmerkom s petimi skupinami kolestilana (3, 6, 9, 12 in 15 g/dan) in placebom je kolestilan pri odmerku 6 g/dan in več prikazal od odmerka odvisno znižanje ravni fosforja v serumu.
Hypocalcaemia/hypercalcaemia
Hipokalciemija/hiperkalciemija
Colestilan also binds bile acids, thereby lowering the serum LDL-cholesterol concentration.
Kolestilan veže tudi želodčne kisline in tako zniža koncentracije LDL-holesterola v serumu.
BindRen has no or negligible influence on the ability to drive and use machines.
Zdravilo BindRen nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Patients previously on other phosphate binders who are switched to BindRen should start taking 6-9 g per day (2-3 g three times daily).
Bolniki, ki so predhodno dobivali druge vezalce fosfatov, sedaj pa so prešli na zdravilo BindRen, naj začnejo z odmerkom 6-9 g na dan (2-3 g trikrat na dan).
Colestilan was also associated in dose-dependent reduction in serum uric acid, with a mean reduction of 43 micromol/L after one year of treatment.
Sečna kislina v serumu Kolestilan so povezovali tudi z znižanjem sečne kisline v serumu, odvisno od odmerka, s povprečnim znižanjem 43 mikromolov/l po enem letu zdravljenja.
The most frequently reported adverse reactions were nausea, dyspepsia and vomiting (all common).
Najpogostejši neželeni učinki so bili navzea, dispepsija in bruhanje (vsi pogosti).
No in vivo data are available on the possible interaction of BindRen on the absorption of the immunosuppressant medicinal products mycophenolate mofetil, ciclosporin or tacrolimus.
Podatki in vivo glede možnih interakcij zdravila BindRen na absorpcijo imunosupresivov, kot so mikofenolat mofetil, ciklosporin ali takrolimus, niso na voljo.
Talk to your doctor or pharmacist if during your treatment with BindRen, any of the following applies to you: - you experience constipation, since your doctor may wish to monitor your bowel function to detect potential side effects (see section 4).
Pogovorite se s svojim zdravnikom ali farmacevtom, če med zdravljenjem z zdravilom BindRen opazite naslednje: - pojavi se vam zaprtje, ker želi vaš zdravnik spremljati delovanje vašega želodca in odkriti morebitne stranske učinke.
Patients who are constipated should be monitored carefully while being treated with BindRen.
Bolnike, ki so zaprti, morate med zdravljenjem z zdravilom BindRen skrbno spremljati.
Aluminium/polychlorotrifluoroethylene/PVC blister.
Pretisni omot aluminij/poliklorotrifluoroetilen/PVC.
Colestilan binds to the phosphorus from food in your digestive tract to prevent it from being absorbed into your blood.
Kolestilan se v prebavilih veže na fosfor iz hrane in prepreči njegovo absorpcijo v kri.
Do not use this medicine after the expiry date stated on the box or the sachet after the abbreviation “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli ali vrečici poleg oznake »EXP«.
Serum phosphorus concentrations should be monitored.
Nadzirati je treba koncentracije fosforja v serumu.
Foil laminate (polyethylene terephthalate/polyethylene/aluminium foil/polyethylene/polyvinylidene chloride) sachets.
Vrečice iz laminata iz (polietilen tereftalata/polietilena/aluminijeve folije/polietilena/poliviniliden klorida).
Gastrointestinal haemorrhage
Gastrointestinalna krvavitev
In very rare cases, intestinal obstruction and ileus/subileus have been observed in patients during treatment with BindRen.
V zelo redkih primerih so pri bolnikih med zdravljenjem z zdravilom BindRen opazili črevesno zaporo in ileus/subileus.
• Recent history of peritonitis in peritoneal dialysis patients
• peritonitisom v novejši anamnezi pri bolnikih na peritonealni dializi,
Caution should be exercised when treating patients with conditions which predispose to gastrointestinal haemorrhage, such as recent history of gastrointestinal haemorrhage, gastrointestinal ulcers, gastritis, diverticulosis, colitis and haemorrhoids.
Previdnost je potrebna pri zdravljenju bolnikov s stanji, zaradi katerih so bolj nagnjeni k gastrointestinalnim krvavitvam, kot je gastrointestinalna krvavitev v nedavni anamnezi, gastrointestinalna razjeda, gastritis, divertikuloza, kolitis in hemoroidi.
The least squares mean reduction from baseline to week 12 as compared to placebo was 0.16, 0.21, 0.19 and 0.37 mmol/L at 6, 9, 12 and 15 g/day respectively.
Povprečno znižanje po metodi najmanjših kvadratov od izhodišča do 12. tedna v primerjavi s placebom je bilo 0,16; 0,21; 0,19 in 0,37 mmol/l pri 6, 9, 12 in 15 g/dan.
Do not use this medicine after the expiry date stated on the box, the bottle label or the blister after the abbreviation “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, nalepki plastenke ali pretisnem omotu poleg oznake »EXP«.
High density polyethylene (HDPE) bottles, with a polypropylene cap and an induction seal.
Plastenke iz polietilena visoke gostote (HDPE), s polipropilensko zaporko in indukcijskim zvarom.
What BindRen looks like and contents of the pack
Izgled zdravila BindRen in vsebina pakiranja
Urticaria, rash, pruritus, dry skin
urtikarija, izpuščaj, pruritus, suha koža
The daily dose of BindRen tablets should be taken in three equally divided doses with or immediately after meals with a sufficient amount of water to aid swallowing.
Dnevni odmerek zdravila BindRen tablete je treba vzeti v treh enakomerno razdeljenih odmerkih z obrokom ali takoj po njem z zadostno količino vode za lažje požiranje.
BindRen is for oral use.
Zdravilo BindRen je za peroralno uporabo.
After one year, the mean serum phosphorus level was 1.89 mmol/L with a significant reduction from baseline of 0.39 mmol/L and responder rate (phosphorus level <1.78 mmol/L) was 44%.
Po enem letu je bila povprečna raven fosforja v serumu 1,89 mmol/l z znatnim znižanjem od izhodišča za 0,39 mmol/l in stopnjo odzivnosti (raven fosforja <1,78 mmol/l)
However, if you cannot swallow the contents of a whole sachet at once you can divide the contents of the sachet dose into smaller portions.
Vendar pa lahko vsebino vrečice razdelite na manjše porcije, če cele ne morete pogoltniti naenkrat.
BindRen does not contain calcium, and has no effect on serum calcium concentrations on treatment for up to one year.
Zdravilo BindRen ne vsebuje kalcija in nima učinka na koncentracije kalcija v serumu pri zdravljenju, ki traja do eno leto.
Due to the high in vitro binding potential between BindRen and levothyroxine, closer monitoring of thyroid stimulating hormone (TSH) levels in patients receiving BindRen and levothyroxine is recommended.
Zaradi visokega potenciala vezave in vitro med zdravilom BindRen in levotiroksinom se priporoča skrbno spremljanje ravni ščitnico stimulirajočega hormona (TSH) pri bolnikih, ki prejemajo zdravilo
There are no known antidotes to BindRen.
Za zdravilo BindRen ni znanih antidotov.
Fertility No data are available to assess the potential influence of BindRen on fertility.
Plodnost Podatkov za oceno možnega vpliva zdravila BindRen na sposobnost razmnoževanja ni.
Calcium-phosphorus ion product was reduced by at least 0.48 mmol2/L2 at week 12 compared to placebo at doses ≥9 g/day in fixed-dose study and by 1.05 and 0.86 mmol2/L2 at week 12 in two flexible-dose studies.
Produkt ionov kalcija in fosforja se je znižal za vsaj 0,48 mmol2/l2 v 12. tednu v primerjavi s placebom pri odmerkih ≥9 g/dan v študiji s fiksnim odmerkom in za 1,05 in 0,86 mmol2/l2 v 12. tednu v dveh študijah s prilagodljivimi odmerki.
Driving and using machines BindRen has no or negligible influence on the ability to drive or use machines.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo BindRen nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
No data are available to assess the safety and efficacy in breast-feeding women.
Podatkov za oceno varnosti in učinkovitosti pri doječih ženskah ni.
BindRen alone cannot treat this condition and other medicines should be prescribed for you.
Zdravilo BindRen samo ne more pozdraviti te bolezni, zato vam lahko predpišejo druga
Patients with seizure disorders were excluded from clinical trials with BindRen.
Bolniki z motnjami z epileptičnimi napadi so bili izključenih iz kliničnih preskušanj z zdravilom
The daily dose of BindRen granules should be taken in three equally divided doses with or immediately after meals with a sufficient amount of water to aid swallowing.
Dnevni odmerek zdravila BindRen zrnca je treba vzeti v treh enakomerno razdeljenih odmerkih z obrokom ali takoj po njem z zadostno količino vode za lažje požiranje.
Each film-coated tablet contains 1 g of colestilan.
Ena filmsko obložena tableta vsebuje 1 g kolestilana.
How to take BindRen
Kako jemati zdravilo BindRen
Folate deficiency, hypertriglyceridaemia, polydipsia
pomanjkanje folata, hipertrigliceridemija, polidipsija
The most serious adverse reactions were gastrointestinal haemorrhage (uncommon) and constipation (common).
Najbolj resni neželeni učinki so bili gastrointestinalna krvavitev (občasni) in zaprtje (pogosti).